NCT02008929View on ClinicalTrials.gov

to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

MG4101

Ex vivo expanded allogeneic NK cell

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02008929 - to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) | Biotech Hunter | Biotech Hunter